SLC2A4 and type 2 diabetes mellitus: In the setting of type 2 diabetes (T2D), active PPARG increases insulin sensitivity by enhancing healthy adipogenesis and increasing production of adiponectin and GLUT4.49 As such, PPARG agonists like TZDs are standard in T2D therapy.